S1PR3アンタゴニズムは,ROCK1-Drp1シグナル伝達経路を通じて,セプティック急性腎臓損傷における内皮機能障害を改善する
Zhipeng Xu1, Jueyue Yan1, Gan Luo2
1Department of Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Molecular immunology
|February 15, 2026
まとめ
スフィンゴシン-1-フォスファート受容体3 (S1PR3) は,内皮細胞とミトコンドリアを損傷することによって,腎臓損傷を誘導します. 脂質体薬でS1PR3を阻害すると,腎臓機能が保護され,セプシス誘発の急性腎臓損傷が軽減されます.
科学分野:
- 腎臓の病理生理学
- 腸内皮の生物学について
- ミトコンドリア医学とは
背景:
- スフィンゴシン-1-ホスファート受容体3 (S1PR3) は主に内皮細胞に存在し,炎症プロセスに影響を与えます.
- セプティック急性腎損傷 (S-AKI) の発生におけるS1PR3の特定の役割は十分に理解されていません.
- 本研究では,S-AKI.期間中の内皮機能不全におけるS1PR3の機能とメカニズムを調査しています.
研究 の 目的:
- S-AKIにおける内皮機能不全におけるS1PR3の役割を決定する.
- S-AKIの病原化にS1PR3が寄与する根本的なメカニズムを解明する.
- S-AKIにおけるS1PR3アンタゴニストの治療の可能性を評価する.
主な方法:
- セプティック急性腎損傷 (S-AKI) は,リポポリサッカリド (LPS) を使用したマウスで誘発されました.
- 腎臓内皮機能とミトコンドリアの完全性は,フローサイトメトリ,エヴァンズブルー染料検査,伝送電子顕微鏡を用いて評価されました.
- ヒト静脈内皮細胞 (HUVEC) をS1PR3抗体 (TY-52156) とリポソーマル製剤でインビトロ研究で使用した.
主要な成果:
- LPSチャレンジにより,野生型のマウスの血清クレアチニン,血中尿素窒素,S1PR3発現が増加し,S1PR3は内皮細胞に局所化した.
- S1PR3 (S1pr3-/-) が欠けていたマウスは,野生型のマウスと比較して,腎機能の改善,白血球の浸透の減少,ATP生成の増加を示した.
- S1PR3の活性化は,ミトコンドリア機能障害,細胞骨格の変化,および内皮の浸透性の増加と相関する;in vitroでは,TY-52156はこれらの影響を軽減した. リポソーム包装,特にLP-Neg-TY-52156は,有効性を改善し,内皮の漏れや腎機能不全を in vivo で軽減しました.
結論:
- 内皮S1PR3は,S-AKIにおけるミトコンドリア機能障害とバリア障害の重要な要因である.
- S1PR3をリポソーマアンタゴニストで標的にすることは,内皮の完全性を維持し,性腎損傷を軽減するための有望な治療アプローチを提供します.
関連する概念動画
Acute Kidney Injury II: Pathophysiology
1.2K
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.2K
Acute Kidney Injury I: Introduction
828
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
828
Acute Kidney Injury IV: Diagnostic Studies and Prevention
354
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
354
Acute Kidney Injury III: Clinical Manifestations
993
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
993
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Acute Kidney Injury V: Interprofessional Care
369
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
369


